Filip Krag Knop

Filip Krag Knop

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology


  1. 2024
  2. Published

    An Extended Minimal Model of OGTT: estimation of α- and β-cell dysfunction, insulin resistance, and the incretin effect

    Subramanian, V., Bagger, J. I., Harihar, V., Holst, Jens Juul, Knop, Filip Krag & Vilsbøll, Tina, 2024, In: American Journal of Physiology - Endocrinology and Metabolism. 326, 2, p. E182-E205

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Author Response to Letter to the Editor regarding “the Epidemiology of Bile Acid Diarrhea in Denmark” [Response to Letter]

    Ellegaard, A. M., Kårhus, M. L., Knop, Filip Krag & Kårhus, L. L., 2024, In: Clinical Epidemiology. 16, p. 5-6 2 p.

    Research output: Contribution to journalLetterResearchpeer-review

  4. Published

    Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trial

    Løn, N., Engel, S., Damholt, A., Mortensen, B., Haaber, A. B., Wellejus, A. & Knop, Filip Krag, 2024, In: Alimentary Pharmacology and Therapeutics. 59, 3, p. 341-349 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling

    Gether, I. M., Bahne, E., Nerild, H. H., Rehfeld, Jens Frederik, Hartmann, Bolette, Holst, Jens Juul, Vilsbøll, Tina, Sonne, David Peick & Knop, Filip Krag, 2024, In: European Journal of Endocrinology. 190, 4, p. 314-326 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply

    Løn, N., Engel, S., Damholt, A., Wellejus, A. & Knop, Filip Krag, 2024, In: Alimentary Pharmacology and Therapeutics. 59, 4, p. 577-578 2 p.

    Research output: Contribution to journalEditorialResearchpeer-review

  7. Accepted/In press

    Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis – results from a randomized controlled trial (PSORRO)

    Gyldenløve, Mette, Sørensen, J. A., Fage, S., Meteran, H., Skov, Lone, Zachariae, Claus, Knop, Filip Krag, Nielsen, M. L. & Egeberg, Alexander, 2024, (Accepted/In press) In: Journal of the American Academy of Dermatology.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer

    Nerild, H. H., Brønden, A., Haddouchi, A. E., Ellegaard, A., Hartmann, Bolette, Rehfeld, Jens Frederik, Holst, Jens Juul, Sonne, David Peick, Vilsbøll, Tina & Knop, Filip Krag, 2024, In: Diabetes, Obesity and Metabolism. 26, 4, p. 1252-1263

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

    Baekdal, M., Nielsen, S. W., Hansen, C. P., Storkholm, J. H., van Hall, Gerrit, Hartmann, Bolette, Holst, Jens Juul, Vilsbøll, Tina, Lund, A. & Knop, Filip Krag, 2024, In: Diabetes Care. 47, 1, p. 71-80 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program

    Andersen, Camilla, Larsen, J. H., Jensen, J., Omar, M., Nouhravesh, N., Kistorp, Caroline Michaela Nervil, Tuxen, C., Gustafsson, Finn, Knop, Filip Krag, Forman, Julie Lyng, Davidovski, Filip Søskov, Jensen, Lars Thorbjørn, Højlund, K., Køber, Lars Valeur, Antonsen, L., Poulsen, M. K., Schou, Morten & Møller, J. E., 2024, In: American Heart Journal. 271, p. 84-96 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies

    Rosenstock, J., Cariou, B., Eliasson, J., Frappin, G., Kaltoft, M. S., Montanya, E. & Knop, Filip Krag, 2024, In: Diabetes, Obesity and Metabolism. 26, 2, p. 532-539 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...54 Next

ID: 40100368